{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Age-Related+Macular+Degeneration+%28AMD%29",
    "query": {
      "condition": "Age-Related Macular Degeneration (AMD)"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 890,
    "total_pages": 89,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Age-Related+Macular+Degeneration+%28AMD%29&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-05-22T08:50:00.714Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02357342",
      "title": "Sirolimus Versus Anti-Vascular Endothelial Growth Factor (antiVEGF) for Wet AMD",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Age-Related Macular Degeneration"
      ],
      "interventions": [
        {
          "name": "Sirolimus",
          "type": "DRUG"
        },
        {
          "name": "Standard of Care intravitreal injections of anti-VEGF",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Maturi, Raj K., M.D., P.C.",
      "sponsor_class": "INDIV",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 40,
      "start_date": "2015-04",
      "completion_date": "2017-01",
      "has_results": true,
      "last_update_posted_date": "2017-06-22",
      "last_synced_at": "2026-05-22T08:50:00.714Z",
      "location_count": 1,
      "location_summary": "Indianapolis, Indiana",
      "locations": [
        {
          "city": "Indianapolis",
          "state": "Indiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02357342"
    },
    {
      "nct_id": "NCT07582042",
      "title": "Lesion-tailored, Fundus-controlled Perimetry in Geographic Atrophy (GA).",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Geographic Atrophy From Age-related Macular Degeneration"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "University of Utah",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "65 Years",
        "maximum_age": "90 Years",
        "sex": "ALL",
        "summary": "65 Years to 90 Years"
      },
      "enrollment_count": 50,
      "start_date": "2026-05-15",
      "completion_date": "2029-08-01",
      "has_results": false,
      "last_update_posted_date": "2026-05-18",
      "last_synced_at": "2026-05-22T08:50:00.714Z",
      "location_count": 1,
      "location_summary": "Salt Lake City, Utah",
      "locations": [
        {
          "city": "Salt Lake City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07582042"
    },
    {
      "nct_id": "NCT05283941",
      "title": "Pistachios and Neural Macular Pigment",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Macular Degeneration",
        "Retinal Degeneration",
        "Retinal Diseases",
        "Eye Diseases"
      ],
      "interventions": [
        {
          "name": "Pistachio Group",
          "type": "DIETARY_SUPPLEMENT"
        }
      ],
      "intervention_types": [
        "DIETARY_SUPPLEMENT"
      ],
      "sponsor": "Tufts University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "40 Years to 70 Years"
      },
      "enrollment_count": 40,
      "start_date": "2022-06-10",
      "completion_date": "2023-11-30",
      "has_results": false,
      "last_update_posted_date": "2023-03-09",
      "last_synced_at": "2026-05-22T08:50:00.714Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05283941"
    },
    {
      "nct_id": "NCT07105228",
      "title": "Incidence of Retinal Vasculitis Among Patients Receiving Aflibercept: A US Real-World Evidence Study",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Retinal Vasculitis"
      ],
      "interventions": [
        {
          "name": "aflibercept 2mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Regeneron Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 290000,
      "start_date": "2025-07-15",
      "completion_date": "2025-09-15",
      "has_results": false,
      "last_update_posted_date": "2025-10-10",
      "last_synced_at": "2026-05-22T08:50:00.714Z",
      "location_count": 1,
      "location_summary": "Tarrytown, New York",
      "locations": [
        {
          "city": "Tarrytown",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07105228"
    },
    {
      "nct_id": "NCT01579760",
      "title": "Intravitreal Aflibercept Injection for Radiation Retinopathy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Radiation Retinopathy",
        "Macular Edema"
      ],
      "interventions": [
        {
          "name": "Aflibercept every 2 months",
          "type": "DRUG"
        },
        {
          "name": "Aflibercept monthly",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Washington University School of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 9,
      "start_date": "2012-11",
      "completion_date": "2019-03-27",
      "has_results": false,
      "last_update_posted_date": "2019-04-25",
      "last_synced_at": "2026-05-22T08:50:00.714Z",
      "location_count": 2,
      "location_summary": "St Louis, Missouri • Houston, Texas",
      "locations": [
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01579760"
    },
    {
      "nct_id": "NCT01526070",
      "title": "Study of Bimonthly VEGF Trap-Eye Compared to As-needed Administration or Other Therapy for Exudative Age-Related Macular Degeneration",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Exudative Age-related Macular Degeneration"
      ],
      "interventions": [
        {
          "name": "Intravitreal injection of Aflibercept",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Stanford University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 142,
      "start_date": "2012-01",
      "completion_date": "2014-07",
      "has_results": false,
      "last_update_posted_date": "2014-11-18",
      "last_synced_at": "2026-05-22T08:50:00.714Z",
      "location_count": 1,
      "location_summary": "Palo Alto, California",
      "locations": [
        {
          "city": "Palo Alto",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01526070"
    },
    {
      "nct_id": "NCT06779773",
      "title": "A Study to Learn How Avacincaptad Pegol (Izervay™) is Used in Clinical Practice in People Who Have Geographic Atrophy",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Geographic Atrophy",
        "Macular Degeneration"
      ],
      "interventions": [
        {
          "name": "Avacincaptad pegol (ACP)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Astellas Pharma Global Development, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 1000,
      "start_date": "2025-01-22",
      "completion_date": "2030-01-31",
      "has_results": false,
      "last_update_posted_date": "2026-04-21",
      "last_synced_at": "2026-05-22T08:50:00.714Z",
      "location_count": 65,
      "location_summary": "Phoenix, Arizona • Scottsdale, Arizona • Encino, California + 59 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Encino",
          "state": "California"
        },
        {
          "city": "Laguna Hills",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06779773"
    },
    {
      "nct_id": "NCT00312351",
      "title": "A Clinical Trial to Explore the Safety and Efficacy of Three Different Doses of Pegaptanib Sodium in Patients With Wet Age-Related Macular Degeneration (AMD)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Macular Degeneration"
      ],
      "interventions": [
        {
          "name": "Pegaptanib sodium",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eyetech Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 262,
      "start_date": "2006-04",
      "completion_date": "2006-11",
      "has_results": false,
      "last_update_posted_date": "2007-01-15",
      "last_synced_at": "2026-05-22T08:50:00.714Z",
      "location_count": 1,
      "location_summary": "Charlotte, North Carolina",
      "locations": [
        {
          "city": "Charlotte",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00312351"
    },
    {
      "nct_id": "NCT06132035",
      "title": "Study to Evaluate the Safety of CG-P5 Peptide Eye Drops in Patients Diagnosed With Age-related Wet Macular Degeneration",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Age-related Wet Macular Degeneration"
      ],
      "interventions": [
        {
          "name": "CG-P5 peptide",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Aflibercept Injection [Eylea]",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Caregen Co. Ltd.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 45,
      "start_date": "2023-12-22",
      "completion_date": "2025-08",
      "has_results": false,
      "last_update_posted_date": "2025-02-07",
      "last_synced_at": "2026-05-22T08:50:00.714Z",
      "location_count": 7,
      "location_summary": "Manchester, Connecticut • Deerfield Beach, Florida • Augusta, Georgia + 4 more",
      "locations": [
        {
          "city": "Manchester",
          "state": "Connecticut"
        },
        {
          "city": "Deerfield Beach",
          "state": "Florida"
        },
        {
          "city": "Augusta",
          "state": "Georgia"
        },
        {
          "city": "Carmel",
          "state": "Indiana"
        },
        {
          "city": "Fargo",
          "state": "North Dakota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06132035"
    },
    {
      "nct_id": "NCT00438243",
      "title": "Pilot Study of the Effect of Topical Bromfenac Ophthalmic Solution 0.09%in Patients With Acute Post-operative Cystoid Macular Edema.",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Cystoid Macular Edema"
      ],
      "interventions": [
        {
          "name": "Bromfenac (Xibrom)",
          "type": "DRUG"
        },
        {
          "name": "Refresh Plus",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Johns Hopkins University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2008-05",
      "completion_date": "2010-09",
      "has_results": false,
      "last_update_posted_date": "2016-07-04",
      "last_synced_at": "2026-05-22T08:50:00.714Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00438243"
    }
  ]
}